This topic contains a solution. Click here to go to the answer

Author Question: A patient taking montelukast (Singulair) for the last 2 months has the following blood laboratory ... (Read 149 times)

Beheh

  • Hero Member
  • *****
  • Posts: 520
A patient taking montelukast (Singulair) for
 
  the last 2 months has the following blood laboratory test values. Which value do you report to the prescriber immediately?
  a. White blood cell count of 10,500 cells/mm3
  b. Lactate dehydrogenase 950 IU/L
  c. Potassium 3.6 mEq/L
  d. Hematocrit 32

Question 2

What condition is a major cause of long-term high blood pressure?
 
  a. Atherosclerosis
  b. Bleeding disorders
  c. Chronic liver disease
  d. Diabetes insipidus



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

juliaf

  • Sr. Member
  • ****
  • Posts: 344
Answer to Question 1

ANS: B

Answer to Question 2

ANS: A




juliaf

  • Sr. Member
  • ****
  • Posts: 344

 

Did you know?

Prostaglandins were first isolated from human semen in Sweden in the 1930s. They were so named because the researcher thought that they came from the prostate gland. In fact, prostaglandins exist and are synthesized in almost every cell of the body.

Did you know?

Disorders that may affect pharmacodynamics include genetic mutations, malnutrition, thyrotoxicosis, myasthenia gravis, Parkinson's disease, and certain forms of insulin-resistant diabetes mellitus.

Did you know?

Looking at the sun may not only cause headache and distort your vision temporarily, but it can also cause permanent eye damage. Any exposure to sunlight adds to the cumulative effects of ultraviolet (UV) radiation on your eyes. UV exposure has been linked to eye disorders such as macular degeneration, solar retinitis, and corneal dystrophies.

Did you know?

For pediatric patients, intravenous fluids are the most commonly cited products involved in medication errors that are reported to the USP.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library